

Express Mail No. EL589230408US  
Date of Deposit: October 29, 2001

Attorney Docket No. 18242-507 (VI-7)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Hammond et al.  
SERIAL NUMBER: 09/543,188  
FILING DATE: April 5, 2000  
FOR: Prion-binding Ligands and Methods of Using Same  
EXAMINER: N. Davis  
ART UNIT: 1647

Commissioner for Patents and Trademarks  
Washington, D.C. 20231

October 29, 2001

RECEIVED  
JAN 2 8 2002  
TECH CENTER 1600/2900

TRANSMITTAL LETTER

In compliance with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, Applicants submit herein:

Response to Notice to Comply with Sequence Listing Requirement Under 37 CFR §§1.821-1.825 (1 page.);  
Copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 page);  
Nucleotide/Amino Acid Sequence Submission, paper copy (10 pages);  
Computer Readable Form (1 disk);  
Statement in Support of Computer Readable Form Submission under 37 C.F.R. § 1.821(f) (1 page);  
Preliminary Amendment (3 pages);  
Return Postcard.

Applicants believe that no fee is required for the filing of the present paper. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference 18242-507 (VI-7).

Respectfully submitted,

*Ivor R. Elrifi, Reg. No. 39,529*


Ivor R. Elrifi (Reg. No. 39,529)  
Attorney for the Applicants  
c/o MINTZ LEVIN

One Financial Center  
Boston, Massachusetts 02111  
Telephone: (617) 542-6000  
Fax (617) 542 2241

*Ser:*

DISK TO STIC

DATE:



TRA 1587470v1

BEST AVAILABLE COPY

Express Mail Label No.: EL585230408US  
Date of Deposit: October 29, 2001

Attorney Docket No.: 18242-507

# 11/B  
9/01  
2-2-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Hammond et al.  
PATENT & TRADEMARK OFFICE  
NUMBER: 09/543,188  
FILING DATE: April 5, 2000  
FOR: Prion-binding Ligands and Methods of Using Same

EXAMINER: N. Davis

ART UNIT: 1642

October 29, 2001  
Boston, Massachusetts

Commissioner for Patents and Trademarks  
Washington, D.C. 20231

RECEIVED  
JAN 28 2002  
TECH CENTER 1600/2900

**RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING  
REQUIREMENT UNDER 37 CFR §§ 1.821 - 1.825**


In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures mailed September 28, 2001, applicants enclose a paper copy of the supplemental sequence listing, a computer readable copy of the sequence listing, a statement in support of the computer readable format, and a preliminary amendment directing incorporation of the sequence listing into the application. A response to this Notice is due on October 28, 2001, which falls on a Sunday. Therefore, this response is due on or before Monday, October 29, 2001.

Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

*Ivor R. Elrifi, Reg. No. 45,409*  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

*for:*


**Notice to Comply**

Application No.

09/593188

Applicant(s)

Examiner

Art Unit

TECH CENTER 1600/2900

JAN 28 2002

RECEIVED

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: *Need sequence identifier for the peptide ligand in claim 15*

**Applicant Must Provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**